IQVIA appointed EU Market Access and Reimbursement Advisor
Filed with ASX · · 3 pages · English
Earlier from OncoSil Medical
- Preliminary Final Report
- Appendix 4C & Quarterly Update
- Response to Price Query
- Oncosil submits Clinical Study Report to Notified Body
- Clinical Programme Update
Later from OncoSil Medical
- R&D Refund - 2018 Financial Year
- PanCo Study Interim Analysis
- CE Marking Update
- Update - CE Marking Application
- Response to ASX Price Query
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical